<DOC>
	<DOCNO>NCT03058757</DOCNO>
	<brief_summary>The aim study evaluate effectiveness safety neoadjuvant intravesical mitomycin-C instillation non-muscle invasive bladder cancer patient</brief_summary>
	<brief_title>The Effectiveness Safety Neoadjuvant Intravesical Mitomycin-C Instillation</brief_title>
	<detailed_description>Study Design : Intervention Model : Single Group Assignment Masking : Open Label Primary Outcome Measures : Recurrence-free survival neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group control group . Secondary Outcome Measures : Progression-free survival neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group control group . Time recurrence neoadjuvant intravesical mitomycin-C 40mg/20ml instillation group control group . Change tumor size neoadjuvant intravesical mitomycin-C 40mg/20ml instillation . Safety neoadjuvant intravesical mitomycin-C 40mg/20ml instillation .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>The subject undergo transurethral resection tumor diagnosis bladder cancer Male female age 18 18 year 85 year diagnose bladder cancer Normal bone marrow function : Hemoglobin &gt; 10 g/dL , ANC &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 Normal renal function : serum creatinine ≤ 1.4 mg/dL Normal liver function : Bilirubin ≤ 1.5 time upper normal limit AST/ALT ≤ 1.8 time upper normal limit Alkaline phosphatase ≤ 1.8 time upper normal limit Subjects voluntarily decide participate sign write informed consent Nonurothelial carcinoma Muscle invasive bladder cancer Subjects underwent intravesical mitomycinC instillation diagnosis bladder cancer within 3 year Prior hypersensitivity reaction history mitomycinC Neurogenic bladder Subjects underwent chemotherapy due cancer within 6 month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>